Goldman finds it hard going for Qiagen convertible as Deutsche reveals losses
Goldman Sachs sold a $150m convertible bond on Wednesday for Qiagen, a Dutch biotech company, but only after repricing the issue when investors rejected the aggressive price range.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts
